Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 1300 Morris Park Ave, Bronx, NY 10461, USA
- Website
- oligomerix.com
- Founded
- 2006
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Bolden Therapeutics Inc. | Providence, RI | — |
| Adrx, Inc. | Thousand Oaks, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Virogenics, Inc. | San Diego, CA | 238990 All Other Specialty Trade Contractors |
| Department Of Molecular Immunology | Huntington Beach, CA | — |
| Cognition Therapeutics, Inc. | Harrison, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Oligomerix Inc. is a biotechnology company located in West Harrison, New York, focused on developing innovative pharmaceutical interventions for neurodegenerative diseases, specifically Alzheimer's disease. Registered in SAM.gov since 2007, the company operates as a for-profit corporate entity specializing in the research and development of small molecule drugs targeting tau protein aggregation. The company's primary research focus is on creating disease-modifying treatments for Alzheimer's and related tauopathies, with a strategic approach to developing oral, economically viable therapeutic interventions.
Through federal grant awards from the National Institute on Aging, Oligomerix Inc. has been conducting extensive preclinical and clinical research on its lead compound OLX-07010, a small molecule drug designed to inhibit tau self-association. The company has received multiple project grants totaling nearly $500,000 to support various stages of drug development, including a 26-week rat toxicity study, a 13-week dog toxicity study, and preparations for first-in-human Phase 1 clinical trials. These grants have supported critical research activities such as efficacy and biomarker studies in Alzheimer's mouse models, pharmacological screening, drug manufacturing, and toxicology assessments. The research aims to develop a potentially transformative treatment for Alzheimer's disease, with a focus on creating a drug that is oral, self-administered, and capable of addressing the growing global challenge of neurodegenerative disorders.
Quick answers
Is Oligomerix Inc. registered in SAM.gov?
Yes. Oligomerix Inc.'s SAM.gov registration is active through January 20, 2027.
What is Oligomerix Inc.'s CAGE code?
Oligomerix Inc.'s CAGE code is 4PQQ8, and its Unique Entity ID (UEI) is MHB5HVJVAK87.
What is Oligomerix Inc.'s most recent federal award?
Oligomerix Inc.'s most recent federal grant award is A 13-week oral gavage toxicity study of OLX-07010 in beagle dogs followed by a 4-week recovery period (R44AG091987), from National Institute on Aging (NIH), on August 20, 2025.
On GovTribe
See Oligomerix Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors